Roughly 500 anti-cancer agents will be available for development within the next decade. The Phase I community will face significant challenges making swift and accurate go/no go drug development decisions, due to limited resources for continued clinical development as well as potentially unique profiles that the clinical drug candidates may unfold. It is important to be proactive, anticipating many of the challenges. Maximizing the knowledge base and combining resources to assist in overcoming many of these challenges will be a key component of continued success. Karmanos Cancer Institute (KCI) and University of Maryland Marlene &Stewart Greenebaum Cancer Center (UMGCC) jointly are submitting this application to maximize our strengths as a Phase I Consortium. The combined expertise of both institutions define us as thought leaders in pharmacokinetics (PK), pharmacodynamics (PD), imaging and biostatistics, all necessary components of an efficient and effective phase I program. Both institutions have recognized the greater need for understanding tumor-related targeted drug effects. Drs. LoRusso (KCI Principal Investigator) and Sausville (UMGCC Principal Investigator) have both involved exploration of PD effects of several different classes of agents. Dr. Sausville has developed a PD translational research laboratory at UMGCC to help further develop select PD endpoints for implementation in the clinical trials to be pursued by this consortium. The combined expertise of Drs. LoRusso and Sausville lend collectively at least 40 years experience in preclinical and clinical cancer drug development. Their efforts have led to the development of several commercially available or recently filed agents, including Velcade?1/2, Ontak?1/2, capecitabine, zoledronic acid, gefitinib, lapatanib, and ixabepilone, to name a few. Their programs have recognized that patient resources are valuable and limited, and have had significant success developing and evaluating novel trial designs to minimize patients treated at ineffective doses. The locations of both institutions lend themselves to service inner city populations with large women and minority bases, offering the potential for special population studies. Dr. Shields, our collaborator at KCI, has been a thought leader in PET imaging, with several tracers, including FDG and FLT, to his portfolio. This imaging oriented capacity is yet an additional unique feature available to his consortium. With the continued growth and expansion of both programs, we feel this collaboration will be well positioned for the continued development of novel agents offered through the Cancer Treatment Evaluation Program at the National Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA062487-19
Application #
8234887
Study Section
Special Emphasis Panel (ZCA1-SRRB-K (O1))
Program Officer
Ivy, S Percy
Project Start
1998-03-05
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2014-02-28
Support Year
19
Fiscal Year
2012
Total Cost
$601,787
Indirect Cost
$154,605
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Li, Jing; Kim, Seongho; Sha, Xianyi et al. (2014) Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. Clin Cancer Res 20:3931-44
Liu, Xiaochun; Lorusso, Patricia; Mita, Monica et al. (2014) Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist 19:426-8
Naing, A; Lorusso, P; Fu, S et al. (2013) Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 108:826-30
Shibata, Stephen I; Chung, Vincent; Synold, Timothy W et al. (2013) Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 19:3631-9
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Wu, Jianmei; Wiegand, Richard; LoRusso, Patricia et al. (2013) A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS/MS analysis. J Chromatogr B Analyt Technol Biomed Life Sci 941:100-8
Gojo, Ivana; Perl, Alexander; Luger, Selina et al. (2013) Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs 31:1217-27
Wiegand, Richard; Wu, Jianmei; Shields, Anthony F et al. (2012) Simultaneous determination of 1-(2'-deoxy-2'-fluoro-*-D-arabinofuranosyl) uracil (FAU) and 1-(2'-deoxy-2'-fluoro-*-D-arabinofuranosyl) 5-methyluracil (FMAU) in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 891-892:64-70
Naing, Aung; LoRusso, Patricia; Fu, Siqing et al. (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18:2625-31
Wu, Jianmei; Lorusso, Patricia M; Matherly, Larry H et al. (2012) Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the ?-secretase inhibitor RO4929097. Clin Cancer Res 18:2066-79

Showing the most recent 10 out of 42 publications